Efficacy and Safety of Delgocitinib and Its Impact on Patient’s Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study

Authors

  • Elena Pezzolo Department of Dermatology, San Bortolo Hospital, Vicenza, Italy
  • Raul Armando Luyo Saboya Department of Dermatology, San Bortolo Hospital, Vicenza, Italy
  • Michela Ortoncelli Dermatologic Clinic, Department of Medical Science, University of Turin, Turin, Italy
  • Simone Ribero Dermatologic Clinic, Department of Medical Science, University of Turin, Turin, Italy
  • Federica Gelato Dermatologic Clinic, Department of Medical Science, University of Turin, Turin, Italy
  • Marco Galluzzo Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy; Dermatology Unit, Azienda Ospedaliera Universitaria “Policlinico Tor Vergata”, Rome, Italy
  • Marina Talamonti Dermatology Unit, Azienda Ospedaliera Universitaria “Policlinico Tor Vergata”, Rome, Italy
  • Edoardo Mortato Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
  • Antonio Costanzo Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
  • Luigi Gargiulo Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
  • Alessandra Narcisi Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
  • Matteo Bianco Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
  • Carlotta Gurioli Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
  • Gionathan Orioni Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
  • Camilla Loi Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
  • Niccolò Gori ele, Milan, Italy, 7Dermatology Unit, IRCCS Azienda OspedalieroUniversitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy, 8Section of Dermatology, University Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy
  • Ketty Peris 8Section of Dermatology, University Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy
  • Elena Ippoliti Section of Dermatology, University Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy
  • Giampiero Girolomoni Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
  • Martina Maurelli Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
  • Maria Esposito Unit of Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
  • Sara Triolo Unit of Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy
  • Caterina Foti Unit of Dermatology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy
  • Giorgia Sbarra Unit of Dermatology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy
  • Ersilia Tolino Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Rome, Italy
  • Nevena Skroza Dermatology Unit "Daniele Innocenzi", Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Rome, Italy
  • Andrea Carugno Dermatology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy
  • Nicola Zerbinati Dermatology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy
  • Anna Balato Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy
  • Eugenia Veronica Di Brizzi Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy https://orcid.org/0000-0002-0278-2443
  • Martina Burlando Section of Dermatology, Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy; Dermatology Unit, IRCCS San Martino University Hospital, Genoa, Italy
  • Vito Di Lernia Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
  • Pietro Morrone Provincial Health Authority of Cosenza, Cosenza, Italy
  • Emiliano Antiga Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
  • Maria Concetta Fargnoli Scientific Direction, IRCCS San Gallicano, Dermatological Institute, Rome, Italy
  • Filomena Russo Department of Dermatology Unit, Istituto Dermopatico dell'Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy
  • Francesca Caroppo Pediatric Dermatology Regional Center, Department of Women and Children’s Health (SDB), University of Padua, Padua, Italy; Dermatology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy
  • Laura Fagotto Institute of Dermatology, Santa Maria della Misericordia University Hospital, Udine, Italy
  • Piergiacomo Calzavara-Pinton Dermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy
  • Stefano Bighetti Dermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy https://orcid.org/0009-0006-2781-6909
  • Mariateresa Rossi Dermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy

DOI:

https://doi.org/10.2340/actadv.v106.adv-2026-0765

Keywords:

chronic hand eczema, delgocitinib, physician global assessment, Hand Eczema Severity Index, hand eczema symptom diary, safety and tolerability, efficacy

Abstract

Delgocitinib is a pan-Janus kinase inhibitor approved for moderate-to-severe chronic hand eczema (CHE) in adults. However, real-world evidence remains limited. We prospectively evaluated 149 adult patients (mean age: 46.4 years; 60.4 % female) treated with delgocitinib for chronic hand eczema across 20 Italian dermatology centres between May and November 2025, with a four-month follow-up. Two-thirds of patients were non-occupationally exposed, and>80% had vesicular or atopic chronic hand eczema. At week 4, Physician Global Assessment (PGA)-chronic hand eczema 0/1 and Hand Eczema Severity Index (HECSI)-75 were achieved in 42.3% and 43.8% of patients, increasing significantly to 74.3% and 88.0% at week 16. Pruritus and pain Numerical Rating Scale (NRS) 0/1 were reported in 43.8% and 52.3% of patients at week 4, rising significantly to 74.4% and 86.5% at week 16. Hand Eczema Symptom Diary–Patient Global Impression of Severity (HESD PGI-S) 0/1 increased from 45.6% to 76.6%. Non-occupationally exposed patients showed significantly higher early response rates than occupationally exposed, with attenuation of differences by week 16. HECSI-75 responses were consistent across chronic hand eczema subtypes, particularly vesicular (94.0%) and atopic (90.0%). Treatment was well tolerated, with rare and no severe adverse events reported. These findings support delgocitinib as a rapid, effective and safe treatment option for chronic hand eczema.

Downloads

Download data is not yet available.

References

Apfelbacher C, Bewley A, Molin S, Fargnoli MC, Giménez-Arnau AM, Brignoli L, et al. Prevalence of chronic hand eczema in adults: a cross-sectional survey of over 60 000 respondents from the general population of Canada, France, Germany, Italy, Spain and the UK. Br J Dermatol 2025; 192: 1047–1054.

Thyssen JP, Johansen JD, Linneberg A, Menné T. The epidemiology of hand eczema in the general population – prevalence and main findings *. Contact Derm 2010; 62: 75–87.

Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova‐Fischer I, Arents BWM, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Derm 2022; 86: 357–378.

Molin S, Guttman-Yassky E, Thyssen JP, Bewley A. Chronic Hand Eczema, Real World, and Patient Centricity: A Narrative Review. Acta Derm Venereol 2025; 105: adv42596.

Agner T, Aalto-Korte K, Andersen KE, Foti C, Gimenéz-Arnau A, Goncalo M, et al. European Environmental and Contact Dermatitis Research Group. Classification of hand eczema. J Eur Acad Dermatol Venereo 2015; 29: 2417–2422.

Rönsch H, Schiffers F, Ofenloch R, Weisshaar E, Buse AS, Hansen A, et al. Chronic hand eczema in Europe: Patient experiences and perspectives (CHEPEP) in qualitative interviews. Acad Dermatol Venereol 2023; 37: 1396–1405.

Kouris A, Armyra K, Christodoulou C, Katoulis A, Potouridou I, Tsatovidou R, et al. Quality of life, anxiety, depression and obsessive‐compulsive tendencies in patients with chronic hand eczema. Contact Derm 2015; 72: 367–370.

Apfelbacher CJ, Ofenloch RF, Weisshaar E, Molin S, Bauer A, Mahler V, et al. Chronic hand eczema in Germany: 5‐year follow‐up data from the CARPE registry. Contact Derm 2019; 80: 45–53.

Elias PM. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 1983; 80 Suppl: 44s–49s.

Vindenes HK, Drengenes C, Amin H, Irgens-Hansen K, Svanes C, Bertelsen RJ. Longitudinal analysis of the skin microbiome in association with hand eczema, hand hygiene practices and moisturizer use. J Eur Acad Dermatol Venereol 2024; 38: 2118–2129.

Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther 2019; 32: e12840.

Tancredi V, Buononato D, Caccavale S, Di Brizzi EV, Di Caprio R, Argenziano G, et al. New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis. Int J Mol Sci 2023; 25: 362.

Ch’en PY, Lio PA. Nonsteroidal Approaches for Atopic Dermatitis®: A Clinical Update. Dermatitis 2024; 35: 596–604.

Giménez-Arnau A, Bewley A, Apfelbacher C, Fargnoli MC, Rault B, Morillo A, et al. Physician-Reported Treatment Patterns in Moderate to Severe Chronic Hand Eczema: the RWEAL Multinational Medical Chart Review. Dermatol Ther (Heidelb) 2025; 15: 3577–3592.

Ruzicka T, Lynde CW, Jemec GBE, Diepgen T, Berth-Jones J, Coenraads PJ, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158: 808–817.

Bissonnette R, Worm M, Gerlach B, Guenther L, Cambazard F, Ruzicka T, et al. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. Br J Dermatol 2010; 162: 420–426.

Simpson EL, Silverberg JI, Worm M, Honari G, Masuda K, Syguła E, et al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2024; 90: 1190–1199.

Voorberg AN, Kamphuis E, Christoffers WA, Schuttelaar MLA. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study. Br J Dermatol 2023; 189: 400–409.

Blaya Imbernón D, Finello M, Peñuelas Leal R, Labrandero Hoyos C, Grau Echevarría A, Pérez Zafrilla E, et al. Tralokinumab for Chronic Hand Eczema: A 52 Week Observational Case Series. J Cutan Med Surg 2026: 12034754261431747.

Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet 2024; 404: 461–473.

Gooderham M, Molin S, Bissonnette R, Worm M, Crépy MN, Stingeni L, et al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials. J Am Acad Dermatol 2025; 93: 95–103.

Giménez-Arnau AM, Pinter A, Sondermann W, Reguiai Z, Woolf R, Lynde C, et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial. Lancet 2025; 405: 1676–1688.

World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. JAMA 2025; 333: 71–74.

European Medicines Agency. Anzupgo® (delgocitinib): Summary of Product Characteristics. 2025. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/anzupgo?utm_source=chatgpt.com

STROBE statement. [cited 2023 March 1]. Available from: https://www.strobe-statement.org/checklists/cohort-studies

Silverberg JI, Agner T, Baranowski K, Plohberger U, Thoning H, Arbuckle R, et al. Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity. Arch Dermatol Res 2024; 316: 110.

Yüksel YT, Agner T, Ofenloch R. New evidence on the minimal important change (MIC) for the Hand Eczema Severity Index (HECSI).

Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761–769.

Molin S, Larsen LS, Joensson P, Oesterdal ML, Arbuckle R, Grant L, et al. Development and Psychometric Validation of a Patient-Reported Outcome Measure to Assess the Signs and Symptoms of Chronic Hand Eczema: The Hand Eczema Symptom Diary (HESD). Dermatol Ther (Heidelb) 2024; 14: 643–669.

Basra MKA, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: 27–33.

Ito T, Sugasawa S. Grouped generalized estimating equations for longitudinal data analysis. Biometrics 2023; 79: 1868–1879.

Weißinger S, Oppel E, Kurzen N, Ertl C, Tomsitz D, Pumnea T, et al. A Retrospective Real-World Comparison of Topical Delgocitinib and Localized Cream Psoralen-Ultraviolet A in Chronic Hand Eczema. Dermatol Ther (Heidelb) 2026; 16: 2447–2463.

Downloads

Published

2026-10-07

How to Cite

Pezzolo, E., Luyo Saboya, R. A., Ortoncelli, M., Ribero, S., Gelato, F., Galluzzo, M., … Rossi, M. (2026). Efficacy and Safety of Delgocitinib and Its Impact on Patient’s Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study. Acta Dermato-Venereologica, 106, adv–2026. https://doi.org/10.2340/actadv.v106.adv-2026-0765

Issue

Vol. 106 (2026)

Section

Articles

Categories

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC